Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Obstructive Pulmonary Disease (COPD): later-stage trial registry
11 of 37 indexed Chronic Obstructive Pulmonary Disease (COPD) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #406 of 28,707 conditions by registered trial count.
37 US clinical trials · 11 currently recruiting · #406 of 28,707 conditions by registered trial count
Chronic Obstructive Pulmonary Disease (COPD): 37 US clinical trials tracked, 11 recruiting.
Chronic Obstructive Pulmonary Disease (COPD) is the subject of 37 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 16 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 10 of these trials.
Enrollment posture brief
Registry condition chronic-obstructive-pulmonary-disease-copd
OPEN 11 | RECR 30% | LATE 16 | EARLY 8 | RANK #406 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Substance-Related Disorders (30% recruiting · 64 trials)
Chronic Obstructive Pulmonary Disease (COPD) lists 11 open slots (30% of 37 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Obstructive Pulmonary Disease (COPD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Obstructive Pulmonary Disease (COPD) is recruiting below its size-band peers.
11 of 37 indexed trials (29.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Obstructive Pulmonary Disease (COPD) research.
AstraZeneca accounts for 10 of 37 trials (27%). 23 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Obstructive Pulmonary Disease (COPD) enrolment sits around 317 participants.
Median target enrolment is 317 among the 37 trials that report a genuine target (sentinel values excluded). 8 of those (21.6%) plan for fewer than 100 participants.
-
Chronic Obstructive Pulmonary Disease (COPD) research is mostly interventional.
32 interventional and 5 observational studies make up this index (86.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
37 total, page 1 of 1
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Weill Medical College of Cornell University
NCT01776398
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche
NCT05595642
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
AstraZeneca
NCT07082738
Temple Health Chest Initiative (THCI 2.0)
Temple University
NCT06933758
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca
NCT06878261
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
AstraZeneca
NCT06883305
Multi-Center Clean Air Randomized Controlled Trial in COPD
JHSPH Center for Clinical Trials
NCT06376994
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Johns Hopkins University
NCT07059091
Pulmonary Rehabilitation for Rural Patients With COPD
Mayo Clinic
NCT06847061
Effectiveness of the WearME System for COPD Severity and Respiratory Function
LASARRUS Clinic and Research Center
NCT06751537
Functional Social Support in COPD Self-Management
Medical University of South Carolina
NCT07353034
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
AstraZeneca
NCT05742802
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
AstraZeneca
NCT06040086
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
AstraZeneca
NCT05158387
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
AstraZeneca
NCT05166889
The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)
Weill Medical College of Cornell University
NCT03583099
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
NCT00877383
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
Sunovion Respiratory Development
NCT02276222
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Mylan
NCT02518139
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Novartis Pharmaceuticals
NCT01727141
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
Mylan
NCT02512510
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
Teva Branded Pharmaceutical Products R&D
NCT01857323
Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)
VA Office of Research and Development
NCT01102777
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Novartis
NCT00510510
Aides in Respiration Health Coaching for COPD
University of California, San Francisco
NCT02234284
Adherence Study in COPD Patients
AstraZeneca
NCT02864342
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
AstraZeneca
NCT04631016
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
Nephron Pharmaceuticals Corporation
NCT04780984
Use of Respiratory Therapists (RTs) to Improve Outcomes and Quality of Life in Patients With COPD
StratiHealth
NCT02078622
Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial
Beth Israel Deaconess Medical Center
NCT01998724
Sodium Pyruvate Therapy in COPD Patients
Emphy
NCT00262613
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
AstraZeneca
NCT04600505
Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers
Weill Medical College of Cornell University
NCT00565214
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
Sunovion Respiratory Development
NCT04155047
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
University of North Carolina, Chapel Hill
NCT01615484
Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation
Breas Medical
NCT06560411
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
Turino, Gerard, M.D.
NCT00993707
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
| Phase 3 | 14 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Obstructive Pulmonary Disease (COPD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Obstructive Pulmonary Disease (COPD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Obstructive Pulmonary Disease (COPD) page
37 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Chronic Obstructive Pulmonary Disease (COPD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Chronic Obstructive Pulmonary Disease (COPD) trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Obstructive Pulmonary Disease (COPD) condition card totals 37 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.